Immunosuppressive T cells that tumors exploit to evade immunity–a key component of the inhibitory microenvironment.
Tumors actively recruit and expand Tregs through multiple mechanisms: CCL22 secretion, TGF-² production, and metabolic competition. High Treg infiltration correlates with poor prognosis in most solid tumors (with some exceptions like colorectal cancerLoading...).
Tregs suppress anti-tumor immunity through CTLA-4-mediated inhibition of dendritic cellsLoading..., IL-2 consumption (starving effector T cells), and secretion of inhibitory cytokines (IL-10, TGF-²).
What Tregs Do: Regulatory T cells suppress immune responses. They normally prevent autoimmunity, but in tumors, they can suppress anti-cancer immunity.
The Problem: Tumors attract and expand Tregs, creating an immunosuppressive environment that protects cancer from immune attack.
Tregs express high levels of checkpoint molecules, making them both suppressors and targets. Ipilimumab (anti-CTLA-4) depletes intratumoral Tregs via antibody-dependent cellular cytotoxicity (ADCC). This Treg depletion may be as important as enhancing effector T cell function.
Anti-PD-1 has more complex effects on Tregs–it may release both effector T cells and Tregs from suppression. The balance determines net effect, highlighting the need for functional biomarkersLoading... that capture the full immune context.
High Checkpoint Expression: Tregs express high levels of CTLA-4 and PD-1. Anti-CTLA-4 therapy may work partly by depleting or inactivating Tregs.
Functional Question: Are intratumoral Tregs actively using checkpoints to suppress immunity, or just expressing them? Measuring engagement could provide insight into Treg activity.
Applicable Platform: Regulatory T cells express high levels of CTLA-4 and PD-1. QF-Pro's validated checkpoint assays can quantify Treg-mediated checkpoint engagement within specific tumor regions.
Ready to apply: Tregs express high CTLA-4 and PD-1. QF-Pro's validated assays can quantify Treg-mediated checkpoint engagement in tumor regions.
